TY - JOUR
T1 - [A case of distal cholangiocarcinoma with high sensitivity to neoadjuvant chemoradiation therapy].
AU - Haji, Yoichi
AU - Mizuma, Masamichi
AU - Hayashi, Hiroki
AU - Nakagawa, Kei
AU - Okada, Takaho
AU - Otsuka, Hideo
AU - Ottomo, Shigeru
AU - Sakata, Naoaki
AU - Fukase, Koji
AU - Yoshida, Hiroshi
AU - Onogawa, Tohru
AU - Motoi, Fuyuhiko
AU - Naito, Takeshi
AU - Rikiyama, Toshiki
AU - Katayose, Y.
AU - Egawa, Shinichi
AU - Unno, Michiaki
PY - 2011/11
Y1 - 2011/11
N2 - We hypothesized that neoadjuvant chemoradiation therapy for cholangiocarcinoma (NACRAC) using gemcitabine would improve the prognosis of resected cases. Phase II trial of NACRAC is ongoing. We report a very effective case to NACRAC for distal cholangiocarcinoma, which markedly reduced the size and levels of the tumor markers. The patient was a 50- year-old man who presented jaundice. Serum tumor markers were clearly elevated, and abdominal CT scan revealed an enhanced mass in the lower bile duct, a dilatation of the intrahepatic to the middle bile duct and a swollen regional lymph node. After NACRAC, the tumor markers were decreased within a normal range. Also on CT scan, the main tumor was slightly detectable and the swollen node was reduced more than 30% in short diameter. Therefore, the effect of NACRAC was considered PR in RECIST guidelines (ver.1 .1). Pancreaticoduodenectomy was performed 2 weeks after NACRAC. No perioperative complications occurred. Pathological examination showed a good response, Grade 2b on Oboshi-Shimosato's classification. In this case, NACRAC had a good effect in imaging and pathological findings as well as in the tumor markers. Therefore, the neoadjuvant chemoradiation therapy has a potential to improve the prognosis for cholangiocarcinoma.
AB - We hypothesized that neoadjuvant chemoradiation therapy for cholangiocarcinoma (NACRAC) using gemcitabine would improve the prognosis of resected cases. Phase II trial of NACRAC is ongoing. We report a very effective case to NACRAC for distal cholangiocarcinoma, which markedly reduced the size and levels of the tumor markers. The patient was a 50- year-old man who presented jaundice. Serum tumor markers were clearly elevated, and abdominal CT scan revealed an enhanced mass in the lower bile duct, a dilatation of the intrahepatic to the middle bile duct and a swollen regional lymph node. After NACRAC, the tumor markers were decreased within a normal range. Also on CT scan, the main tumor was slightly detectable and the swollen node was reduced more than 30% in short diameter. Therefore, the effect of NACRAC was considered PR in RECIST guidelines (ver.1 .1). Pancreaticoduodenectomy was performed 2 weeks after NACRAC. No perioperative complications occurred. Pathological examination showed a good response, Grade 2b on Oboshi-Shimosato's classification. In this case, NACRAC had a good effect in imaging and pathological findings as well as in the tumor markers. Therefore, the neoadjuvant chemoradiation therapy has a potential to improve the prognosis for cholangiocarcinoma.
UR - http://www.scopus.com/inward/record.url?scp=84858829759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858829759&partnerID=8YFLogxK
M3 - Article
C2 - 22202402
AN - SCOPUS:84858829759
SN - 0385-0684
VL - 38
SP - 2426
EP - 2428
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 12
ER -
